Recruiting

Alzheimer Network

Sponsor:

Washington University School of Medicine

Code:

NCT00869817

Conditions

Alzheimer's Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Study Details

Brief summary:

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

Conditions

Alzheimer's Disease

Study ID

NCT00869817

Start date

Jan, 2009

Status verified date

Jul, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Written informed consent obtained from participant and collateral source prior to any study-related procedures.
  • Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
  • Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
  • Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
  • Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.

Exclusion Criteria:

  • Under age 18
  • Medical or psychiatric illness that would interfere in completing initial and follow-up visits
  • Requires nursing home level care
  • Has no one who can serve as a study informant

Study Design

Enrollment

700 participants

Anticipated

Interventions and Outcome Measures

Arms

1

Mutation Positive

2

Mutation Negative

Primary outcome measure

  • Positive predictive power of a biomarker or group of biomarkers [ Time Frame: Variable follow-up assessment based on age in relation to age at onset of affected parent. ]
  • Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging [ Time Frame: Variable follow-up assessment based on age in relation to age at onset of affected parent ]
  • Clinical markers also examined from clinical interview and cognitive testing [ Time Frame: Variable follow-up assessment based on age in relation to age at onset of affected parent ]

Central Contacts and Locations

Central contacts

Alisha Daniels, MD,MHA

(314) 273-9057

DIAN Obs Admin Core

NEURO-DIANCoordinatingCenter@email.wustl.edu

Locations

Mayo Clinic Jacksonville

Recruiting

Jacksonville, Florida, United States, 32224

Contacts

Ercilia Moncayo

Moncayo.Ercilia@mayo.edu

Twila Morrell, BS

Morrell.Twila@mayo.edu

Principal Investigator:

Gregory S Day, MD

Indiana University-Indiana Alzheimer Disease Center

Recruiting

Indianapolis, Indiana, United States, 46202

Contacts

Jill Buck, RN

317-963-1847jilmbuck@iu.edu

Principal Investigator:

Martin Farlow, MD

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Alexa Coussoule

acoussoule@bwh.harvard.edu

Paola Matos

pmatos1@mgh.harvard.edu

Principal Investigator:

Jasmeer Chhatwal, MD, PhD

Washington University in St. Louis School of Medicine

Recruiting

St Louis, Missouri, United States, 63108

Contacts

McCrae Johnson, RN, MSN

mccrae@wustl.edu

Georgia Stobbs-Cucchi, RN

gstobbs@wustl.edu

Principal Investigator:

Randall Bateman, MD

University of Pittsburgh

Recruiting

Pittsburgh, Pennsylvania, United States, 15260

Contacts

Zana Ikonomovic, MD

412-692-2740ikonomovics@upmc.edu

Principal Investigator:

Sarah Berman, MD, PhD

Butler Hospital

Recruiting

Providence, Rhode Island, United States, 02906

Contacts

Courtney Bodge, PhD

(401) 455-6403cbodge@butler.org

Principal Investigator:

Edward Huey, MD

University of Washington

Recruiting

Seattle, Washington, United States, 98195

Contacts

Sarah Taylor

saraht73@uw.edu

Emmaline Seth

emmaseth@uw.edu

Principal Investigator:

Suman Jayadev, MD

More Information

Sponsor

Washington University School of Medicine

Last update posted

Jul 20, 2026

Last verified

Jul, 2026

Keywords

  • Alzheimer's disease
  • antecedent biomarkers
  • Amyloid Precursor Protein (APP) mutation
  • presenilin I (PS1) mutation
  • presenilin 2 (PS2) mutation
  • Autosomal Dominant Alzheimer's Disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-07-20.